HER2 overexpression correlates with survival after curative resection of pancreatic cancer
Open Access
- 10 June 2009
- journal article
- Published by Wiley in Cancer Science
- Vol. 100 (7) , 1243-1247
Abstract
HER2 overexpression has been linked to clinical outcomes in several solid tumors, such as breast cancer. However, the correlation between HER2 overexpression and survival in pancreatic carcinoma remains unclear. The impact of HER2 overexpression on survival in pancreatic ductal cancer was examined. Immunohistochemical staining of 129 pancreatic cancers without hematogenous metastases or peritoneal dissemination treated by macroscopically curative resection were analyzed in association with survival data. To determine HER2 overexpression in this pancreatic cancer series, the polyclonal antibody included in HercepTest, which is used worldwide for clinical examination of HER2 overexpression in breast cancer, was used. Immunoreactivity was classified according to the scale presented in the HercepTest Scoring Guidelines. Twenty‐two cases (17.1%) had a score of 0, 28 cases (21.7%) had of a score of 1+, 41 cases (31.8%) had a score of 2+, and 38 cases (29.4%) had a score of 3+. Therefore, HER2 overexpression (score 2+ or 3+) was observed in 79 cases (61.2%). Patients with HER2 overexpression tumors had significantly shorter survival times than those with HER2 normal expression (score 0 or 1+) tumors (median survival time, 14.7 vs 20.7 months, respectively; P = 0.0078 on the log‐rank test). On multivariate survival analysis, HER2 overexpression remained an independent prognostic factor (hazard ratio, 1.806; P = 0.0258). A significant percentage of pancreatic cancers were demonstrated to have HER2 overexpression, and overexpression of this tyrosine kinase receptor proved to be an independent factor for a worse prognosis. These results should encourage further investigation of treatments using new molecular targeting agents against HER2 protein to improve the survival of pancreatic cancer patients. (Cancer Sci 2009; 100: 1243–1247)Keywords
This publication has 20 references indexed in Scilit:
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2006
- Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with GemcitabineClinical Cancer Research, 2006
- HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric CancerDigestive Diseases and Sciences, 2006
- Copy Number of Chromosome 17 but Not HER2 Amplification Predicts Clinical Outcome of Patients With Pancreatic Ductal AdenocarcinomaJournal of Clinical Oncology, 2004
- Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neuCancer Investigation, 2004
- Chromosome aberrations in solid tumorsNature Genetics, 2003
- Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu StatusLaboratory Investigation, 2002
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985